Cerebral Palsy ; physiopathology ; rehabilitation ; Child ; Disability Evaluation ; Humans ; Motor Skills ; Movement ; Muscle Spasticity ; physiopathology ; rehabilitation ; Neuropsychological Tests

BACKGROUND: The improvement in production technology of new materials including artificial ligament reduces material rupture caused by fatigue and histocompatibility-related synovitis and other complications, leading to a wide application of artificial ligament. OBJECTIVE: To evaluate the histocompatibility and clinical curative effects of reconstruction of the anterior cruciate ligament (ACL) of the knee with ligament advanced reinforcement system (LARS) artificial ligament using arthroscopy. DESIGN: A completely randomized clinical design. SETTING: Department of Orthopedics, Second Affiliated Hospital of Soochow University. PARTICIPANTS: Thirty-two cases of ACL injury received LARS artificial ligament in the Department of Orthopedics, Second Affiliated Hospital of Soochow University From June 2005 to June 2006 and were recruited for this study. The 32 patients averaged 21 years old and were injured in sports. Prior to surgery, MRI showed injury to ACL and semilunar valve in all patients. Written informed consent for therapeutic contents was obtained from each patient. METHODS: Thirty-two patients with injury to ACL of the knee underwent arthroscopic ACL reconstruction. LARS was used to reconstruct the ACL. The LARS was produced by Laboratoire d'Application et de Recherche Scientifique, France (Certification No. CE0459, 1SO9002-EN46002). Artificial ligament was made of polyethylene terephthalate, which had the material type L021201 (left knee) and L021202 (right knee). Artificial ligament was designed to imitate the anatomic structure and biomechanical principle of artificial ligament with specification No. AC120 2BL(left knee) and No. AC120 2BR(right knee). The lot number for artificial ligament in China [import 03460468 (in 2004)]. All reconstructions were performed by a group of physicians who have worked for more than 10 years in the Department of Orthopedics, Second Affiliated Hospital of Soochow University and directed by a physician titled with doctor's tutor and chief physician. All included physicians were qualified to perform the surgery. The protocol of treatment was approved by the hospital's Ethics Committee. MAIN OUTCOME MEASURES: Biocompatibility of LARS artificial ligament was observed. Patients were followed up for 24 months on average to score knee function by Lysholm test and subjective satisfaction by Tegner test. RESULTS: All of 32 cases were followed up. The follow-up periods were 18 months (3 cases), 20 months (7 cases), 24 months (8 cases), 28 months (12 cases) and 30 months (2 cases). No complications, such as acute or chronic synovitis, LARS artificial ligament rupture, or limited range of motion were found. The knee joint function was ideal with the range of motion [0° to (128±11.56)°]. The postoperative scores with 85.6 ± 2.24 were significandy higher than the preoperative scores with 45.3±1.31 according to the Lysholm knee joint function evaluation system (P < 0.05). The instability of every knee disappeared with anterior drawer sign negative. Tegner's scores were also increased. CONCLUSION: The biocompatibility of LARS is optimal. LARS artificial ligament reconstruction showed excellent knee joint function and subjective satisfaction degree.

BACKGROUND: Of the many growth factors that can enhance bone formation, the bone morphogenic proteins (BMPs) are probably the most effective and most widely studied for applications requiring new bone growth. To analyze the effects, the gold standard is patient randomized control trials, however, only BMP-2 and BMP-7 have reached this level of investigation. OBJECTIVE: In this meta analysis the recent findings concerning the application of recombinant human bone morphogenic protein-2 (rhBMP-2) in tissue engineering and gene therapy, the options of its transfer means, as well as the ideal time of delivery is discussed. RETRIEVAL STRATEGY: The relevant articles published between January 1997 and December 2006 were searched for in Pubmed database by researcher of this article with the key words "recombinant human bone morphogenic proteins (rhBMPs), tissue engineering, gene therapy" in English. A total of 81 articles were selected and reviewed by the standards of: ① Having close relations with the application of rhBMP-2 in tissue engineering and gene therapy; ②The most recently published articles and articles in authority journals were chosen in the same field. Exclusion criteria: repetitive studies. LITERATURE EVALUATION: The main sources of literature are the application of rhBMP-2 in tissue engineering and gene therapy. Among the 52 selected articles, 12 are reviews or meeting reports, others are clinical or elementary experimental studies. DATA SYNTHESIS: BMPs are members of the TGF- β superfamily, which are released by osteoprogenitor cells and typically improve bone growth. The use of scaffolds, cells, and growth factors for bone regeneration is called bone tissue engineering. The application of rhBMP-2 in tissue engineering holds great promise for the augmentation and manipulation of bone and soft tissue repair. One potential alternative to direct rhBMP-2 delivery is to develop a biologic cellular delivery vehicle via gene therapy to enhance bone formation. The application of rhBMP-2 in gene therapy holds great promise for the augmentation and manipulation of bone and soft tissue repair. The research indicated that the dosing, time, and transfer mode of rhBMP-2 to the desired targets remain a facing challenge. Further studies should focus on the ideal dosing, time and method of delivery, which should be easily and reliably displayed, cost effective, and clearly controlled. CONCLUSION: The future of bone and soft tissue repair will likely be based on biologic augmentation of healing and tissue regeneration. The use of rhBMP-2 holds great promise for the augmentation and manipulation in tissue engineering and gene therapy.

Previous studies have proved that the effect of statins in both primary and secondary prevention of ischemic stroke, however, whether acute ischemic stroke needs to be treated with statins and the effect of statins pretreatment on acute ischemic stroke remain unclear. This article reviews the recent representative studies in this field, and analyzes the effects of the application of statins in the treatment of acute ischemic stroke on prognosis.

Objective:To evaluate the present situation and trend of antifungal medicines used in 34 hospitals in Wuhan area. Methods:The sales volume,market share,DDDs and DDC of antifungal medicines in 34 hospitals in Wuhan area during 2012 and 2014 were statistically analyzed. Results:The consumption sum and growth rate of the medicines were increased year by year, and those of pyrrolic medicines were the highest. The sales volume of voriconazole ranked the first. The DDDs of clotrimazole vaginal tablets and nifuratel-nysfungin suppositories ranked the top two. Conclusion:The consumption of antifungal medicines in Wuhan area has been increased greatly and the consumption structure is relatively stable. The utilization evaluation of antifungal medicines should be enhanced. Antifungal medicines should be rationally used to prevent or slow down the spread of drug resistant bacteria.

Cancer cachexia is a state of highly wasting in the terminal stages of cancer, which is characterized by the depletion of adipose tissue, muscle wasting and body weight loss.Loss of fat depots is more prominent than muscle wasting and often precedes.The enhancement of lipolysis, free fatty acids oxidation and white adipose tissue browning, the reduction of lipogenesis, lipid deposition and adipogenesisare important factors causing fat loss.Tumor necrosis factor α, interleukin-6 and zinc α2-glycoprotein are mediators involved in the process of depletion of adipose tissue, thus the drugs targetingthese mediators show a good promise for the treatment of cancer cachexia.The attention paid to the mechanism of depletion of adipose tissue contributes to the development of new therapeutic methods and drugs.

AIM:28 patients with congestive heart failure (CHF) were selected in this studyThe therapeutic scheme was as follows:after withdrawal of other vasodilators,urapidil was given in dose of 100～400?g/min intravenous drip;in severe case,the administration continued for 24～72 h;treatment lasted 3～6 daysThe patients'blood pressure,heart rate and LVEF were measured before and after treatmentRESULTS:The patients'clinical manifestations were markedly improved with a total effective rate of 89%LVEF was improved obviously too and the product of systolic pressure and heart rate was decreasedCONCLUSION:Urapidil is a vasodilator with slight side effects,reliable effectiveness and moderate action,and has undoubted therapeutic effect on CHF

OBJECTIVE:To discuss the development of the core competitive power of domestic vitamin C manufacturing enterprises.METHODS:To analyse the characteristic of vitamin C industry in China and the competitive situation in the new market enviroment after China entry into WTO and to study the value chain of Chinese enterprises.RESULTS&CONCLU?SION:In order to develop the new core competitive power,it is important to breed the core of value chain that is based on in?novation.

In both clinical and animal experiments,it has been confirmed that the inflammation in heart is involved in the development of heart injury after the ischemia/reperfusion.However,the pro-inflammatory mechanism is extremely complicated.Recently,a growing number of reports indicates that many factors play their roles in the inflammation,such as cytokinemia,inflammatory cells,metabolic product of arachidonic acid and COX et al.They are released/presented in the region of myocardial ischemia/reperfusion and include both ischemic and secondary heart injury.